Sir John Bell

But your report on AI was a bit of a turning point for the UK because you did point out to us that we did have a massive opportunity if we got our skates.

And we do have talent.

But you can't just do it with talent these days.

You need compute and you need data.

So we're trying to assemble those things.

So we think we'll be a big addition to that globally, hopefully.

Yeah.

So, I mean, you seem to be reading my mind, Eric, and we need to recruit you over here because, I mean, this is exactly, this is one of our big projects that we've got that we're

we're leaning into.

We all experienced in COVID the ins and outs of vaccines, what works, what doesn't work.

But what became very clear is that we don't really know anything about vaccines.

Basically, you put something together and you hope the trial works.

You've got no intermediate steps.

So we're building a really substantial immunophenotyping capability that will start to interrogate the different arms of the immune response at a molecular level so that we can use a combination of human challenge models.

So we've got a big human challenge model facility here.

Use human challenge models with pathogens.

and with associated vaccines to try and interrogate which bits of the immune response are responsible for protection or therapy of particular immunologically mediated diseases or infectious diseases.

And a crucial bit to that, and one of the reasons, people have tried this before, but first of all, the depth at which you can interrogate the immune system has changed a lot recently.

You can get a lot more data.

But secondly, this is again where the AI becomes important because it isn't going to be a simple, oh, it's the T cells.